Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 3/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | MMP13 | P45452 | 1/20 | 0.41 |
| ▸ | TP53 | P04637 | 3/20 | 0.41 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.41 |
| ▸ | RORC | P51449 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26102356 | 1.00 | GPR119 (0.49) | GPR119KMT2AMAPK1MMP13TP53 | |
| SCHEMBL16026535 | 0.90 | ESR2 (0.44) | GPR119KMT2AMAPK1PDE4BRORC | |
| SCHEMBL17519223 | 0.89 | RORC (0.44) | GPR119KMT2AMAPK1MMP13PDE4B | |
| SCHEMBL3694375 | 0.89 | RORC (0.44) | GPR119KMT2AMAPK1MMP13PDE4B | |
| SCHEMBL28844910 | 0.89 | RORC (0.49) | GPR119MAPK1PDE4BRORC | |
| SCHEMBL3694373 | 0.89 | RORC (0.44) | GPR119KMT2AMAPK1MMP13PDE4B | |
| SCHEMBL3318358 | 0.89 | MEN1 (0.49) | KMT2AMAPK1TP53PDE4BMEN1 | |
| SCHEMBL19745334 | 0.88 | MAPK1 (0.50) | GPR119MAPK1RORC | |
| SCHEMBL5651780 | 0.88 | MAPK1 (0.50) | GPR119MAPK1RORC | |
| SCHEMBL28225677 | 0.88 | MAPK1 (0.50) | GPR119MAPK1RORC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4423090-A2 | ANTAGONISTS OF GPR39 PROTEIN | Vasocardea, Inc. (US) | 2024-09-04 | — | — | EP | disclosed |
| WO-2023076219-A2 | ANTAGONISTS OF GPR39 PROTEIN | VASOCARDEA, INC. (US) | 2023-05-04 | — | — | WO | disclosed |
| WO-2023076219-A2 | ANTAGONISTS OF GPR39 PROTEIN | VASOCARDEA, INC. (US) | 2023-05-04 | — | — | WO | disclosed |
| US-20130005710-A1 | AMINOPYRIDINE DERIVATIVE | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2013-01-03 | — | — | US | disclosed |
| US-20060264420-A1 | Compounds, compositions, and methods | CYTOKINETICS, INC. (US) | 2006-11-23 | — | — | US | disclosed |
| EP-1539180-A4 | COMPOUNDS, COMPOSITIONS, AND METHODS | CYTOKINETICS INC (US) | 2006-08-30 | — | — | EP | disclosed |
| EP-1682534-A2 | PYRIMIDIN-4-ONE COMPOUNDS, COMPOSITIONS, AND METHODS | Cytokinetics, Inc. (US) | 2006-07-26 | — | — | EP | disclosed |
| EP-1663219-A2 | USE OF INDOLE-DERIVED COMPOUNDS FOR THE PREPARATION OF A MEDICAMENT THAT CAN BE USED TO TREAT DISEASES RELATED TO THE SPLICING PROCESS | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (FR) | 2006-06-07 | — | — | EP | disclosed |
| US-20050197327-A1 | Compounds, compositions, and methods | CYTOKINETICS, INCORPORATED | 2005-09-08 | — | — | US | disclosed |
| EP-1539180-A2 | COMPOUNDS, COMPOSITIONS, AND METHODS | Cytokinetics, Inc. (US) | 2005-06-15 | — | — | EP | disclosed |
| WO-2005041888-A2 | PYRIMIDIN-4-ONE COMPOUNDS, COMPOSITIONS AND METHODS | CYTOKINETICS, INC. (US) | 2005-05-12 | — | — | WO | disclosed |
| WO-2005023255-A2 | USE OF INDOLE-DERIVED COMPOUNDS FOR THE PREPARATION OF A MEDICAMENT THAT CAN BE USED TO TREAT DISEASES RELATED TO THE SPLICING PROCESS | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (FR) | 2005-03-17 | — | — | WO | disclosed |
| US-20040048853-A1 | Compounds, compositions, and methods | CYTOKINETICS, INC. | 2004-03-11 | — | — | US | disclosed |
| WO-2004018058-A2 | COMPOUNDS, COMPOSITIONS, AND METHODS | CYTOKINETICS, INC. (US) | 2004-03-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060264420-A1 | Compounds, compositions, and methods | ALPP, PCNA, MKI67 | GPR119 2716/4885KMT2A 1458/4885MAPK1 2739/4885 |
| US-20130005710-A1 | AMINOPYRIDINE DERIVATIVE | DCX, NR0B1, NR4A1 | GPR119 1116/4885KMT2A 171/4885MAPK1 750/4885 |
| US-20050197327-A1 | Compounds, compositions, and methods | ALPP, PCNA, MKI67 | GPR119 2991/4885KMT2A 2023/4885MAPK1 3091/4885 |
| US-20040048853-A1 | Compounds, compositions, and methods | ALPP, PCNA, MKI67 | GPR119 2716/4885KMT2A 1458/4885MAPK1 2739/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.